

#3
NW
Docket No.: PF-0450-1 DIV

"Express Mail" mailing label number EL 856 156 385 US I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated and is addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on August 9, 2001.

By: Nancy Ramos Printed: Nancy Ramos



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: HUMAN PREPRONEUROTENSIN/NEUROMEDIN N

Serial No.: To Be Assigned Filing Date: Herewith

Examiner: To Be Assigned Group Art Unit: To Be Assigned

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in parent application Serial No. 09/0002,114, filed December 31, 1997, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the

documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: 9 August 2001

signing for:

David G. Streeter
David G. Streeter, Ph.D.
Reg. No. 43,168
Direct Dial Telephone: (650) 845-5741

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office				Atty Docket No.		Serial No.	
				PF-0450-1 DIV		To Be Assigned	
LIST OF REFERENCES CITED BY APPLICANTS				Applicants			
(Use several sheets if necessary)				Lal et al.			
				Filing Date		Group	
				Herewith		To Be Assigned	
U.S. Patent Documents							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Foreign Patent Documents							
							Translation
		Document	Date	Country	Class	Subclass	Yes No
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1	Kislauskis, E., et al., "The Rate Gene Encoding Neurotensin and Neuromedin N," <u>The Journal of Biological Chemistry</u> , 263(10):4963-4968 (1988)					
	2	Rovere, C., et al., "Evidence that PC2 is the Endogenous Pro-neurotensin Convertase in rMTC 6-23 Cells and that PC1- and PC2-transfected PC12 Cells Differentially Process Pro-neurotensin," <u>The Journal of Biological Chemistry</u> , 271(19):11368-11375 (1996)					
	3	Vincent, J.P., "Neurotensin Receptors: Binding Properties, Transduction Pathways, and Structure," <u>Cellular and Molecular Neurobiology</u> , 15(5):501-512 (1995)					
	4	Carraway, R. and Leeman, S., "Characterization of Radioimmunoassayable Neurotensin in the Rat," <u>The Journal of Biological Chemistry</u> , 251(22):7045-7052 (1976)					
	5	Dolais-Kitabgi, J., et al., "Effect of Neurotensin on Insulin, Glucagon, and Somatostatin Release from Isolated Pancreatic Islets," <u>Endocrinology</u> , 105:256-260 (1979)					
	6	Kitabgi, P., "Effects of Neurotensin on Intestinal Smooth Muscle: Application to the Study of Structure-Activity Relationships," <u>Ann. NY Acad. Sci.</u> 400:37-55 (1982)					
	7	Rostene, W.H. and Alexander, M.J., "Neurotensin and Neuroendocrine Regulation," <u>Frontiers in Neuroendocrinology</u> , 18:115-173 (1997)					
	8	Lambert, P., et al., "Anatomy and Mechanisms of Neurotensin-Dopamine Interactions in the Central Nervous System," <u>Ann. NY Acad. Sci.</u> , 757:377-389 (1995)					
	9	Fernandez, A., et al., "Characterization of Neurotensin-Like Immunoreactivity in Human Basal Ganglia: Increased Neurotensin Levels in Substantia Nigra in Parkinson's Disease," <u>Peptides</u> , 16(2):339-346 (1995)					
Examiner			Date Considered				
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.</p>							

[illegible]

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.